Sandra L Kane-Gill1,2,3, Marlies Ostermann4, Jing Shi5, Emily L Joyce6,7,8, John A Kellum6,9. 1. School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. slk54@pitt.edu. 2. Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, PA, USA. slk54@pitt.edu. 3. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. slk54@pitt.edu. 4. Department of Critical Care, King's College London, Guy's and St Thomas' Hospital, London, UK. 5. Department of Biostatistics, Walker Bioscience, Carlsbad, CA, USA. 6. Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, PA, USA. 7. Department of Pediatrics (Nephrology), University of Pittsburgh, Pittsburgh, PA, USA. 8. UPMC Children's Hospital, Pittsburgh, PA, USA. 9. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
INTRODUCTION: A drug combination that has gained recent attention for an additive risk of nephrotoxicity is vancomycin plus piperacillin-tazobactam. Clinicians need to better understand whether tubular cell stress occurs with piperacillin-tazobactam administration to establish whether renal injury associated with this combination is a valid clinical concern. OBJECTIVE: An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin-tazobactam alone, and vancomycin plus piperacillin-tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types. METHODS: A secondary analysis of the prospective, multicenter Sapphire study (ClinicalTrials.gov identifier NCT01209169) including 35 intensive care units (ICUs) in North America and Europe was performed. Critically ill adult patients at risk for acute kidney injury (AKI) were included. Urinary [TIMP-2]∙[IGFBP7] was measured serially. Patients who received vancomycin alone, piperacillin-tazobactam alone, or vancomycin plus piperacillin-tazobactam were grouped according to their maximum AKI stage within 3 days of the first drug dose. RESULTS: Of 723 critically ill adults admitted to the ICU, 46% received either piperacillin-tazobactam (n = 110), vancomycin (n = 156), or both (n = 67). The urinary [TIMP-2]∙[IGFBP7] was highest on day 1 for the combination group. AKI stage 2/3 occurred more frequently in patients receiving the drug combination than in those receiving piperacillin-tazobactam alone (p = 0.03) but not vancomycin alone (p = 0.29). Risk of death or dialysis at 9 months was greatest for vancomycin plus piperacillin-tazobactam (48%) and similar for patients receiving vancomycin alone (29%) or piperacillin-tazobactam alone (35%) (p = 0.03 for unadjusted and p = 0.048 after adjusting for covariates). CONCLUSION: After exposure to piperacillin-tazobactam and vancomycin in combination, there was a greater release of AKI biomarkers in patients who develop AKI than with piperacillin-tazobactam or vancomycin monotherapy and the combination is associated with possible increased long-term adverse outcomes.
INTRODUCTION: A drug combination that has gained recent attention for an additive risk of nephrotoxicity is vancomycin plus piperacillin-tazobactam. Clinicians need to better understand whether tubular cell stress occurs with piperacillin-tazobactam administration to establish whether renal injury associated with this combination is a valid clinical concern. OBJECTIVE: An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin-tazobactam alone, and vancomycin plus piperacillin-tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types. METHODS: A secondary analysis of the prospective, multicenter Sapphire study (ClinicalTrials.gov identifier NCT01209169) including 35 intensive care units (ICUs) in North America and Europe was performed. Critically ill adult patients at risk for acute kidney injury (AKI) were included. Urinary [TIMP-2]∙[IGFBP7] was measured serially. Patients who received vancomycin alone, piperacillin-tazobactam alone, or vancomycin plus piperacillin-tazobactam were grouped according to their maximum AKI stage within 3 days of the first drug dose. RESULTS: Of 723 critically ill adults admitted to the ICU, 46% received either piperacillin-tazobactam (n = 110), vancomycin (n = 156), or both (n = 67). The urinary [TIMP-2]∙[IGFBP7] was highest on day 1 for the combination group. AKI stage 2/3 occurred more frequently in patients receiving the drug combination than in those receiving piperacillin-tazobactam alone (p = 0.03) but not vancomycin alone (p = 0.29). Risk of death or dialysis at 9 months was greatest for vancomycin plus piperacillin-tazobactam (48%) and similar for patients receiving vancomycin alone (29%) or piperacillin-tazobactam alone (35%) (p = 0.03 for unadjusted and p = 0.048 after adjusting for covariates). CONCLUSION: After exposure to piperacillin-tazobactam and vancomycin in combination, there was a greater release of AKI biomarkers in patients who develop AKI than with piperacillin-tazobactam or vancomycin monotherapy and the combination is associated with possible increased long-term adverse outcomes.
Authors: Megan K Luther; Tristan T Timbrook; Aisling R Caffrey; David Dosa; Thomas P Lodise; Kerry L LaPlante Journal: Crit Care Med Date: 2018-01 Impact factor: 7.598
Authors: Diane M Gomes; Carmen Smotherman; Amy Birch; Lori Dupree; Bethany J Della Vecchia; Dale F Kraemer; Christopher A Jankowski Journal: Pharmacotherapy Date: 2014-04-18 Impact factor: 4.705
Authors: Bhagyashri Navalkele; Jason M Pogue; Shigehiko Karino; Bakht Nishan; Madiha Salim; Shantanu Solanki; Amina Pervaiz; Nader Tashtoush; Hamadullah Shaikh; Sunitha Koppula; Jonathan Koons; Tanveer Hussain; William Perry; Richard Evans; Emily T Martin; Ryan P Mynatt; Kyle P Murray; Michael J Rybak; Keith S Kaye Journal: Clin Infect Dis Date: 2016-10-20 Impact factor: 9.079
Authors: Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel Journal: Br J Clin Pharmacol Date: 2008-11 Impact factor: 4.335
Authors: Joseph Carreno; Tori Smiraglia; Christopher Hunter; Ellis Tobin; Ben Lomaestro Journal: Int J Antimicrob Agents Date: 2018-08-10 Impact factor: 5.283
Authors: Ryan M Rivosecchi; John A Kellum; Joseph F Dasta; Michael J Armahizer; Scott Bolesta; Mitchell S Buckley; Amy L Dzierba; Erin N Frazee; Heather J Johnson; Catherine Kim; Raghavan Murugan; Pamela L Smithburger; Adrian Wong; Sandra L Kane Gill Journal: Ann Pharmacother Date: 2016-10-01 Impact factor: 3.154
Authors: Kianoush Kashani; Ali Al-Khafaji; Thomas Ardiles; Antonio Artigas; Sean M Bagshaw; Max Bell; Azra Bihorac; Robert Birkhahn; Cynthia M Cely; Lakhmir S Chawla; Danielle L Davison; Thorsten Feldkamp; Lui G Forni; Michelle Ng Gong; Kyle J Gunnerson; Michael Haase; James Hackett; Patrick M Honore; Eric A J Hoste; Olivier Joannes-Boyau; Michael Joannidis; Patrick Kim; Jay L Koyner; Daniel T Laskowitz; Matthew E Lissauer; Gernot Marx; Peter A McCullough; Scott Mullaney; Marlies Ostermann; Thomas Rimmelé; Nathan I Shapiro; Andrew D Shaw; Jing Shi; Amy M Sprague; Jean-Louis Vincent; Christophe Vinsonneau; Ludwig Wagner; Michael G Walker; R Gentry Wilkerson; Kai Zacharowski; John A Kellum Journal: Crit Care Date: 2013-02-06 Impact factor: 9.097
Authors: Luca Molinari; Fabienne Heskia; Sadudee Peerapornratana; Claudio Ronco; Louis Guzzi; Seth Toback; Robert Birch; Hadi Beyhaghi; Thomas Kwan; J Patrick Kampf; Donald M Yealy; John A Kellum Journal: Crit Care Med Date: 2021-10-01 Impact factor: 9.296
Authors: Nuala J Meyer; Michael G S Shashaty; Todd A Miano; Sean Hennessy; Wei Yang; Thomas G Dunn; Ariel R Weisman; Oluwatosin Oniyide; Roseline S Agyekum; Alexandra P Turner; Caroline A G Ittner; Brian J Anderson; F Perry Wilson; Raymond Townsend; John P Reilly; Heather M Giannini; Christopher V Cosgriff; Tiffanie K Jones Journal: Intensive Care Med Date: 2022-07-14 Impact factor: 41.787